Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,891 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Cancer Patients Clear all
Completed Phase 2 Interventional

Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy

NCT00004149
View directory record Official record
Conditions
Prostate Cancer
Interventions
arsenic trioxide
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
Up to 120 Years · Male only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
3
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 30, 2026, 8:11 PM EDT
Completed Phase 3 Interventional Results available

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005947
View directory record Official record
Conditions
Prostate Cancer
Interventions
sipuleucel-T, Placebo
Biological
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
34
States / cities
Duarte, California • Loma Linda, California • Rancho Mirage, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2010 · Synced Oct 30, 2026, 8:11 PM EDT
Recruiting Not applicable Interventional

A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer

NCT07225309
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Colorectal Cancer, Thyroid Cancer, Breast Cancer Stage III, Breast Cancer Stage IV, Prostate Cancer Stage III, Prostate Cancer Stage IV, Colorectal Cancer Stage III, Colorectal Cancer Stage IV, Thyroid Cancer Stage III, Thyroid Cancer Stage IV
Interventions
Meaning-Centered Psychotherapy for Latinos /MCP-L
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 30, 2026, 8:11 PM EDT
Terminated No phase listed Observational

S0437 Long-Term Follow-Up of Patients Who Were Diagnosed With Prostate Cancer on PCPT

NCT00288106
View directory record Official record
Conditions
Prostate Cancer
Interventions
Follow-up
Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
55 Years to 120 Years · Male only
Enrollment
961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
52
States / cities
Fort Lauderdale, Florida • Jupiter, Florida • Miami Beach, Florida + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Oct 30, 2026, 8:11 PM EDT
Completed Phase 1 Interventional Results available

Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients

NCT03120832
View directory record Official record
Conditions
Prostate Cancer
Interventions
PAN-301-1
Biological
Lead sponsor
Sensei Biotherapeutics, Inc.
Industry
Eligibility
21 Years to 85 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Homewood, Alabama • Beverly Hills, California • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2021 · Synced Oct 30, 2026, 8:11 PM EDT
Active, not recruiting Phase 2 Interventional

Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

NCT05168618
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Atezolizumab, Cabozantinib S-malate
Biological · Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 30, 2026, 8:11 PM EDT
Completed Phase 1 Interventional

Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate Cancer

NCT02151760
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
18F-DCFPyL
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 30, 2026, 8:11 PM EDT
Withdrawn Phase 2 Interventional

Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer

NCT01188408
View directory record Official record
Conditions
Prostate Cancer
Interventions
Liposome Entrapped Docetaxel (LE-DT)
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 30, 2026, 8:11 PM EDT
Terminated Phase 2 Interventional Results available

Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer

NCT00103376
View directory record Official record
Conditions
Prostate Cancer
Interventions
Velcade, LH-RH Agonist, Androgen Receptor Antagonists
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
4
States / cities
Loma Linda, California • Charleston, South Carolina • Columbia, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 30, 2026, 8:11 PM EDT
Active, not recruiting Phase 1 Interventional

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

NCT07118176
View directory record Official record
Conditions
Anal Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Cholangiocarcinoma, Colorectal Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Head and Neck Carcinoma, Hematopoietic and Lymphatic System Neoplasm, Hepatocellular Carcinoma, Lung Carcinoma, Malignant Adrenal Gland Neoplasm, Malignant Brain Neoplasm, Malignant Neoplasm of Unknown Primary, Malignant Solid Neoplasm, Malignant Testicular Neoplasm, Malignant Uterine Neoplasm, Neuroendocrine Neoplasm, Ovarian Carcinoma, Pancreatic Carcinoma, Penile Carcinoma, Pleural Carcinomatosis, Primary Peritoneal Carcinoma, Prostate Carcinoma, Salivary Gland Carcinoma, Sarcoma, Skin Carcinoma, Solitary Fibrous Tumor, Thymus Carcinoma, Thyroid Gland Carcinoma, Thyroid Gland Medullary Carcinoma, Urothelial Carcinoma, Vaginal Carcinoma
Interventions
Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46, Positron Emission Tomography
Procedure · Other · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 30, 2026, 8:11 PM EDT
Completed Phase 2 Interventional Results available

Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer

NCT01543776
View directory record Official record
Conditions
Castration-resistant Prostate Cancer, Stage IV Prostate Cancer
Interventions
abiraterone acetate
Drug
Lead sponsor
University of Chicago
Other
Eligibility
Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Evanston, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 30, 2026, 8:11 PM EDT
Completed No phase listed Observational

Imaging Biomarkers to Validate Response in Enzalutamide-Treated mCRPC

NCT02677376
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
18F-Sodium Fluoride (NaF)
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 30, 2026, 8:11 PM EDT
Completed Phase 2 Interventional

Safety Study of Hemospan® in Prostatectomy Patients

NCT00425334
View directory record Official record
Conditions
Blood Loss, Surgical, Prostate Cancer, Surgery
Interventions
Hemospan (MP4OX), Ringer's lactate
Drug
Lead sponsor
Sangart
Industry
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2013 · Synced Oct 30, 2026, 8:11 PM EDT
Terminated Phase 1 Interventional

Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors

NCT04182516
View directory record Official record
Conditions
Advanced/Metastatic Solid Tumors
Interventions
NMS-03305293
Drug
Lead sponsor
Nerviano Medical Sciences
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 30, 2026, 8:11 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer

NCT00323882
View directory record Official record
Conditions
Prostate Cancer, Neoplasm Metastasis
Interventions
MDX-010
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Oct 30, 2026, 8:11 PM EDT
Completed Phase 3 Interventional

Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer

NCT04742361
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer Recurrent
Interventions
[18F]PSMA-1007
Drug
Lead sponsor
ABX advanced biochemical compounds GmbH
Industry
Eligibility
18 Years and older · Male only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
Rochester, Minnesota • Houston, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 30, 2026, 8:11 PM EDT
Completed Phase 2 Interventional

Exisulind Versus Placebo After Surgical Removal of the Prostate

NCT00166426
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Exisulind
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 16, 2009 · Synced Oct 30, 2026, 8:11 PM EDT
Terminated Phase 2 Interventional Results available

ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate Cancer

NCT01119118
View directory record Official record
Conditions
Prostate Cancer
Interventions
ZD4054
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 30, 2026, 8:11 PM EDT
Withdrawn Phase 2 Interventional

Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel

NCT02035124
View directory record Official record
Conditions
Advanced Prostate Cancer
Interventions
BKM 120, Cabazitaxel
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Fort Myers, Florida • Omaha, Nebraska • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Oct 30, 2026, 8:11 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

NCT04644068
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5, Non-small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer, Gastric Cancer, Biliary Cancer, Cervical Cancer, Endometrial Cancer, Small Cell Lung Cancer Only in Module 5
Interventions
AZD5305, Paclitaxel, Carboplatin, T- Dxd, Dato-DXd, Camizestrant
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 30, 2026, 8:11 PM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 30, 2026, 8:11 PM EDT
Completed No phase listed Observational

Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data

NCT00578409
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Male only
Enrollment
758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2015 · Synced Oct 30, 2026, 8:11 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen

NCT01046916
View directory record Official record
Conditions
Prostate Cancer
Interventions
TAK-700
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Ann Arbor, Michigan • Portland, Oregon • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Oct 30, 2026, 8:11 PM EDT
Active, not recruiting Phase 3 Interventional

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NCT05050084
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Bicalutamide, Buserelin, Darolutamide, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Radiation Therapy, Relugolix, Triptorelin
Drug · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
2,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
567
States / cities
Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 432 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 30, 2026, 8:11 PM EDT